GSK To Launch Mepolizumab For Severe Asthma By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
First interleukin-5 drug approved for adults with severe asthma that cannot be controlled by other treatments; sales force will only target specialists.
You may also be interested in...
Walmsley: GSK Is 'Prepared' And 'Ready' For US Advair Generic Launch
GlaxoSmithKline is poised for a challenging 2018, with an interchangeable Advair generic expected to launch, but GSK believes growth from new products will make up some of the loss. US Advair sales could be slashed to £750m from £1.6bn in 2017.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.